Roivant Sciences, Inc.
132 articles with Roivant Sciences, Inc.
-
Roivant to Host Investor Call at 8:00 AM ET on Wednesday, March 15 to Review Results from ADORING 2 Phase 3 Trial in Atopic Dermatitis
3/14/2023
Roivant Sciences announced that it will host a live investor call and webcast at 8:00 AM ET on Wednesday, March 15 to review topline results from the ADORING 2 study, one of two replicate Phase 3 studies in atopic dermatitis.
-
Covant Therapeutics Announces the Formation of its Scientific Advisory Board to Support Platform and Pipeline Advancement
3/7/2023
Covant Therapeutics, an innovative covalent drug discovery company incubated by Roivant Sciences, announced the formation of its Scientific Advisory Board.
-
The 2024 presidential candidate sat down with BioSpace in an exclusive interview to outline the key points of his campaign - including his thoughts on the FDA.
-
Vivek Ramaswamy, the founder of Roivant Sciences, is officially running for president, the GOP hopeful announced Tuesday.
-
Roivant Sciences Announces Change to its Board of Directors
2/22/2023
Roivant Sciences announced that its founder Vivek Ramaswamy has stepped down from the company’s board of directors to focus on his U.S. presidential campaign.
-
Roivant Sciences Announces Pricing of Upsized Public Offering of Common Shares
2/3/2023
Roivant Sciences (Nasdaq: ROIV) today announced the pricing of an upsized underwritten public offering of 26,666,666 of its common shares at a price to the public of $7.50 per share.
-
Roivant Sciences Announces Proposed Public Offering of Common Shares - Feb 01, 2023
2/1/2023
Roivant Sciences Ltd. announced that it has commenced an underwritten public offering of $150 million of common shares.
-
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2022 on Monday, February 13, 2023
1/30/2023
Roivant Sciences (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, February 13, 2023, to report its financial results for the third quarter ended December 31, 2022 and provide a corporate update.
-
Roivant Announces Statistically Significant and Clinically Meaningful Results from the Induction Period of TUSCANY-2
1/4/2023
Roivant Sciences (Nasdaq: ROIV) today announced positive results from the induction period of the TUSCANY-2 Phase 2b study of RVT-3101.
-
Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases
12/1/2022
Roivant Sciences (Nasdaq: ROIV) and Pfizer Inc. today announced formation of a new Vant to develop and commercialize PF-06480605 (now RVT-3101).
-
Pfizer and Roivant have joined forces to form yet another Vant. The new entity will initially work to commercialize RVT-3101 for ulcerative colitis.
-
Roivant Sciences Reports Financial Results for the Second Quarter Ended September 30, 2022 and Provides Business Update
11/14/2022
Roivant Sciences Ltd. (Nasdaq: ROIV) today reported its financial results for the second quarter ended September 30, 2022 and provided an update on the Company’s operations.
-
Roivant Sciences Announces Pricing of Primary and Secondary Public Equity Offering
11/8/2022
Roivant Sciences Ltd. announced the pricing of its primary and secondary public offering of 30,000,000 common shares of Roivant, consisting of 20,000,000 common shares offered by Roivant and 10,000,000 common shares offered by the selling shareholders at a price to the public of $5.00 per share for total gross proceeds of $150 million, consisting of total gross proceeds to Roivant of approximately $100 million and total gross proceeds to the selling shareholders of approximately $50 million.
-
Roivant Sciences Announces Proposed Public Equity Offering - November 07, 2022
11/7/2022
Roivant Sciences Ltd., a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare to patients, announced the commencement of a proposed underwritten public offering of $150,000,000 of common shares.
-
Roivant Sciences to Report Financial Results for the Second Quarter Ended September 30, 2022 on Monday, November 14, 2022 and Present at Upcoming Conferences
10/18/2022
Roivant Sciences (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. EST on Monday, November 14, 2022 to report its financial results for the second quarter ended September 30, 2022 and provide a corporate update.
-
Roivant Sciences announced it has discontinued development of several assets following a pipeline reprioritization.
-
Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus
6/28/2022
Roivant Sciences and Pfizer announced the unveiling of Priovant Therapeutics, dedicated to developing and commercializing novel therapies for autoimmune diseases with the greatest morbidity and mortality.
-
Roivant Sciences Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 and Provides Business Update
6/28/2022
Roivant Sciences Ltd. reported its financial results for the fourth quarter and fiscal year ended March 31, 2022 and provided an update on the Company’s operations.
-
Pfizer and Roivant unveiled Priovant Therapeutics to develop and market new therapies for a wide range of autoimmune diseases with high mortality and morbidity rates.
-
Roivant Sciences to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 on Tuesday, June 28, 2022
6/15/2022
Roivant Sciences (Nasdaq: ROIV), a biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today announced that it will host a live conference call and webcast at 8:00 a.m. EDT on Tuesday, June 28, 2022 to report its financial results for the fourth quarter and fiscal year ended March 31, 2022 and provide a corporate update.